Transplantation characteristics of European patients undergoing hematopoietic stem cell transplantation for CD40 ligand deficiency; survivors
Case . | Age at Tx, y . | Donor . | T-cell depletion . | Conditioning . | GvHD . | Follow-up, y . |
---|---|---|---|---|---|---|
2 | 1.2 | MSD | Nil | bu/thio/flu/cy | Nil | 2 |
3 | 2 | MUD | CD34+ | bu/cy/ATG | Nil | 2.8 |
4 | 2 | MUD | Nil | bu/cy/ATG | 1 S | 3.3 |
5 | 3 | MUD | Campath | bu/cy/LFA-1/CD2 | Nil | 5.8 |
6 | 3.5 | MSD | Nil | bu/cy | Nil | 9.3 |
7 | 3.75 | MUD | CD34+ | bu/cy/ATG | 2 S, L | 3.3 |
8 | 4 | MUD | CD34+ | flu/mel/C1H | Nil | 1.2 |
9 | 4 | MUD+ | CD34+ | bu/cy/ATG | 2 S | 2 |
10 | 4 | MSD | Nil | bu/cy | Nil | 4 |
12 | 4.5 | MUD | CD34+ | bu/cy/ATG | Nil | 3.3 |
13 | 4.5 | MUD | Nil | bu/cy/ATG | 2 S | 3.8 |
14 | 4.5 | MSD | Nil | bu/cy | Nil | 3.5 |
16 | 7 | MUD+ | CD34+ | bu/cy/ATG | Nil | 4 |
17 | 7.3 | MSD | Nil | bu/cy | Nil | 1.6 |
18 | 8 | MRD | CD34+ | bu/cy/ATG | Nil | 2 |
19 | 8 | MUD | Nil | bu/cy/ATG | Nil | 2.6 |
20 | 8.7 | MSD | Nil | bu/cy | 2 G | 1.6 |
21 | 9.5 | MSD | Nil | bu/cy | Nil | AR, 5.4 |
22 | 9.5 | MSD | Nil | bu/cy | 1 S | 5 |
23 | 10 | MSD | Nil | bu/cy | Nil | 6.5 |
25 | 11 | MUD | Nil | bu/cy/LFA-1/CD2 | Nil | AR, 6.3 |
26 | 11.5 | MUD | Nil | flu/mel/ATG | 1 S | 4.5 |
31 | 14 | MRD | Nil | TBI/flu/ATG | 2 S | 2.5 |
33 | 15 | MUD | Nil | flu/mel/C1H | 2 S, L | 3 |
34 | 15.7 | MUD+ | Nil | flu/mel/ATG | 1 S, L | AR, 1.7 |
37 | 18 | MUD | Nil | flu/mel/ATG | 2 L | 4.5 |
Case . | Age at Tx, y . | Donor . | T-cell depletion . | Conditioning . | GvHD . | Follow-up, y . |
---|---|---|---|---|---|---|
2 | 1.2 | MSD | Nil | bu/thio/flu/cy | Nil | 2 |
3 | 2 | MUD | CD34+ | bu/cy/ATG | Nil | 2.8 |
4 | 2 | MUD | Nil | bu/cy/ATG | 1 S | 3.3 |
5 | 3 | MUD | Campath | bu/cy/LFA-1/CD2 | Nil | 5.8 |
6 | 3.5 | MSD | Nil | bu/cy | Nil | 9.3 |
7 | 3.75 | MUD | CD34+ | bu/cy/ATG | 2 S, L | 3.3 |
8 | 4 | MUD | CD34+ | flu/mel/C1H | Nil | 1.2 |
9 | 4 | MUD+ | CD34+ | bu/cy/ATG | 2 S | 2 |
10 | 4 | MSD | Nil | bu/cy | Nil | 4 |
12 | 4.5 | MUD | CD34+ | bu/cy/ATG | Nil | 3.3 |
13 | 4.5 | MUD | Nil | bu/cy/ATG | 2 S | 3.8 |
14 | 4.5 | MSD | Nil | bu/cy | Nil | 3.5 |
16 | 7 | MUD+ | CD34+ | bu/cy/ATG | Nil | 4 |
17 | 7.3 | MSD | Nil | bu/cy | Nil | 1.6 |
18 | 8 | MRD | CD34+ | bu/cy/ATG | Nil | 2 |
19 | 8 | MUD | Nil | bu/cy/ATG | Nil | 2.6 |
20 | 8.7 | MSD | Nil | bu/cy | 2 G | 1.6 |
21 | 9.5 | MSD | Nil | bu/cy | Nil | AR, 5.4 |
22 | 9.5 | MSD | Nil | bu/cy | 1 S | 5 |
23 | 10 | MSD | Nil | bu/cy | Nil | 6.5 |
25 | 11 | MUD | Nil | bu/cy/LFA-1/CD2 | Nil | AR, 6.3 |
26 | 11.5 | MUD | Nil | flu/mel/ATG | 1 S | 4.5 |
31 | 14 | MRD | Nil | TBI/flu/ATG | 2 S | 2.5 |
33 | 15 | MUD | Nil | flu/mel/C1H | 2 S, L | 3 |
34 | 15.7 | MUD+ | Nil | flu/mel/ATG | 1 S, L | AR, 1.7 |
37 | 18 | MUD | Nil | flu/mel/ATG | 2 L | 4.5 |
GvHD indicates graft versus host disease grades 1 to 4; MSD, matched sibling donor; bu, busulphan; thio, thiotepa; flu, fludarabine; cy, cyclophosphamide; MUD, matched unrelated donor 10 of 10; CD34+, CD34+ stem cell selection; ATG, rabbit antithymocyte globulin; Campath, CAMPATH-1M; S, skin; LFA-1, anti-LFA-1 antibody; CD2, anti-CD2 antibody; L, liver; mel, melphalan; C1H, alemtuzumab; MUD+, matched unrelated donor 9 of 10; MRD, phenotypically matched related donor; G, gut; AR, autologous reconstitution patient failed to engraft and remains well on IVIG; and TBI, total body irradiation.